EADO 2023 - 19th European Association of Dermato-Oncology Congress
Apr 20 - Apr 22, 2023 | RomeItaly
LARVOL is not affiliated with 19th European Association of Dermato-Oncology Congress and all trademarks, logos, and brand names are property of their respective owners
Showing 35 abstracts linked to Trials
Key demographics, real world responses and safety data for the UK REACT-CEMI (Real-world Evidence of Advanced CSCC Treatment – with CEMIplimab) study
First-in-human intratumoral administration of AS01B in combination with autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and IV nivolumab in patients with refractory advanced melanoma
Is resistance a common event in the treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib? Additional analysis from the pivotal trial BOLT
Clinician- and patient-reported satisfaction with tirbanibulin 1% in comparison with previous topical actinic keratosis medications in routine clinical practice across the U.S. (PROAK study)
Effect of tirbanibulin 1% ointment on Local Skin Reactions according to Fitzpatrick skin type in Actinic Keratosis patients: a post-hoc analysis of pooled data from two Phase III studies
Patient and clinician satisfaction with the use of tirbanibulin in the treatment of Actinic Keratosis in routine clinical practices, and likelihood to consider tirbanibulin again (PROAK study)
Safety and Tolerability of a single 5-day Treatment Cycle of Tirbanibulin Ointment 1% in Large Field (100cm2): A phase I Trial in patients with Actinic Keratosis
Controlled randomized multi center clinical study to assess the efficacy of an emollient PLUS balm containing an Aquaphilus dolomiae extract (ADE-G1) associated with educational program versus real life in xerotic cancer patients.
Real-world patient characteristics, treatment patterns, and outcomes among patients with advanced cutaneous squamous cell carcinoma (aCSCC) treated with cemiplimab at US oncology clinical practices
Intralesional T-VEC in cutaneous B-cell lymphoma
A phase 3 trial comparing fianlimab (antiLAG-3) plus cemiplimab (anti-PD-1) to pembrolizumab in patients with completely resected high-risk melanoma
Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma
Long-term follow-up and subgroup analyses of metastatic melanoma patients treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
Intralesional administration of L19IL2/L19TNF in difficult-to-treat BCC patients shows favorable safety profile and leads to complete remission of tumor lesions
Anti-PD1 antibody cemiplimab combined with pulsed hedgehog inhibitor sonidegib in advanced basal cell carcinoma